BibTex RIS Cite

The role of endothelin-1 and new therapeutic approaches in sepsis and septic shock

Year 2015, Volume: 5 Issue: 3, 178 - 190, 01.10.2015

Abstract

As a systemic inflammatory response to infection, sepsis describes a complex clinical syndrome that results in progressively advance stage, probably evoke septic shock, multiple organ dysfunction syndrome and ultimately cause to death. Sepsis is markedly enhanced by proinflammatory cytokines that can trigger a systemic inflammatory cascade mediated by chemokines, vasoactive amines, complement and coagulation system as well as reactive oxygen species (ROS). In 1988, endothelin (ET)-1 was identified as a vasoactive amine from endothelium which has a 21 amino acid peptide. It has been demonstrated with the experimental and clinical studies that endothelin acts as an important role in sepsis and septic shock pathogenesis. Moreover, endothelin receptor antagonists have been studied as novel therapeutic target for treatment of sepsis and septic shock and according to these studies beneficial results have been obtained . Mitogen-activated protein kinase signal transduction pathway is stimulated by ET-1 which activates a variety of downstream molecules; it is believed that ET-1could play an important role in the development of sepsis, septic shock, and multiple organ dysfunction syndrome by events that can cause increased reactive oxygen species (ROS) production, inflammation, endothelial dysfunction, abnormal vascular tonus, and vascular remodelling.

References

  • Carré JE, Singer M. Cellular energetic metabolism in sepsis: the need for a systems approach. Biochim Biophys Acta. 2008;1777:763-771.
  • Fernandes D, Assreuy J. Nitric oxide and vascular reactivity in sepsis. Shock. 2008;30:10-13.
  • Tsiotou AG, Sakorafas GH, Anagnostopoulos G, Bramis J. Septic shock; current pathogenetic concepts from a clinical perspective. Med Sci Monit. 2005;11:76-85.
  • Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine Chest. 1992;101(6):644-655.
  • Kayaalp O. Otakoidler. Akılcı Tedavi Yönünden Tıbbi Farmakoloji. 13. Baskı. İstanbul: Güneş Tıp Kitabevi; 2012. s. 130-135.
  • Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001;29:1303-1310.
  • Aygen B, Kayabaş Ü, Güven M, Doğanay M, Sümerkan B, Yıldız O. Erciyes Üniversitesi Tıp Fakültesi yoğun bakım üniteleri nozokomial infeksiyonları sürveyansı: Epidemioloji, risk faktörleri ve prognozu etkileyen faktörler. Yoğun Bakım Dergisi. 2001;1:122-30.
  • Tunctan B, Korkmaz B, Sari AN, Kacan M, Unsal D, Serin MS, Buharalioglu CK, Sahan-Firat S, Schunck WH, Falck JR, Malik KU. A novel treatment strategy for sepsis and septic shock based on the interactions between prostanoids, nitric oxide, and 20-hydroxyeicosatetraenoic acid. Antiinflamm Antiallergy Agents Med Chem. 2012;11(2):121-150.
  • Vincent JL, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H, Moreno R, Carlet J, Le Gall JR, Payen D. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med. 2006;34(2):344- 353.
  • Dipiro JT, Talbert LR, Yee GC, Matzke GR,Wells GB, Posey ML. Sepsis and septic shock. Pharmacotherapy. 7th Ed. USA: McGraw-Hill Companies; 2008. p.1943-55.
  • Ünsal D. Sıçanlarda Zimosan ile Oluşan Hipotansiyona Dalak Tirozin Kinazının Katkısının Araştırılması. Mersin Üniversitesi Sağlık Bilimleri Enstitüsü; 2013.
  • Annane D, Bellissant E, Cavaillon JM. Septic shock. Lancet. 2005;365:63-78.
  • Raetz CR, Whitfield C. Lipopolysaccharide endotoxins. Annu Rev Biochem. 2002;71:635-700.
  • Beutler B, Cerami A. Tumor necrosis, cachexia, shock, and inflammation: a common mediator. Annu Rev Biochem. 1988;57:505- 518.
  • Miller SI, Ernst RK, Bader MW. LPS, TLR4 and infectious disease diversity. Nat Rev Microbiol. 2005;3:36-46.
  • Bryant CE, Spring DR, Gangloff M, Gay NJ. The molecular basis of the host response to lipopolysaccharide. Nat Rev Microbiol. 2010;8:8-14.
  • Agnieszka P, Aneta HJ, Kinga B, Ktarzynka K. Co-operation of TLR4 and raft proteins in LPS-induced pro-inflammatory signaling. Cell Mol Life Sci. 2015;72(3):557-581.
  • Reindert N, Tom H, Jos AG. Recognition of LPS by TLR4: Potential for anti-inflammatory therapies. Drugs. 2014;12(7):4260-4273.
  • Ramachandran G. Gram-positive and gram-negative bacterial toxins in sepsis: a brief review. Virulence. 2014;5(1):213-218.
  • Carvalho AC, Freeman NJ. How coagulation defects alter outcome in sepsis. J Crit Illn. 1994;9:51-75.
  • Kidokoro A, Iba T, Fukunaga M, Yagi Y. Alterations in coagulation and fibrinolysis during sepsis. Shock. 1996;5:223-228.
  • Vervloet MG, Thijs LG, Hack CE. Derangements of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock. Semin Thromb Hemost. 1998;24:33-44.
  • Aziz M1, Jacob A, Yang WL, Matsuda A, Wang P. Current trends in inflammatory and immunomodulatory mediators in sepsis. J Leukoc Biol. 2013;93(3):329-342.
  • Bone RC. The pathogenesis of sepsis. Ann Intern Med. 1991;115:457- 469.
  • Zhang Y, Zhao C, He W, Wang Z, Fang Q, Xiao B, Liu Z, Liang G, Yang S. Discovery and evaluation of asymmetrical monocarbonyl analogs of curcumin as antiinflammatory agents. Drug Des Devel Ther. 2014;8:373-382.
  • Sagy M, Al-Qaqaa Y, Kim P. Definitions and pathophysiology of sepsis. Curr Probl Pediatr Adolesc Health Care. 2013;43:260-263.
  • Roth J, De Souza GE. Fever induction pathways: evidence from responses to systemic or local cytokine formation. Braz J Med Biol Res. 2001;34:301-314.
  • Jesmin S, Shimojo N, Yamaguchi N Mowa CN, Oki M, Zaedi S, Sultana SN, Rahman A, Islam M, Sawamura A, Gando S, Kawano S, Miyauchi T, Mizutani T. Effects of protease activated receptor (PAR)2 blocking peptide on endothelin-1 levels in kidney tissues in endotoxemic rat mode. Life Sci. 2014;102:127-133.
  • Keller S, Karaa A, Paxian M Clemens MG, Zhang JX. Inhibition of endothelin- 1-mediated up-regulation of iNOS by bosentan ameliorates endotoxin-induced liver injury in cirrhosis. Shock. 2006;25:306-313.
  • Halliwell B, Gutteridge JMC: Free Radicals in Biology and Medicine. Oxford: Oxford University Press; 2007.
  • Andrades ME, Ritter C, Dal-Pizzol F: The role of free radicals in sepsis development. Front Biosci. 2009;1:277-287.
  • Berger MM, Chioléro RL. Antioxidant supplementation in sepsis and systemic inflammatory response syndrome. Crit Care Med. 2007;35:584-590.
  • Crimi E, Liguori A, Condorelli M, Cioffi M, Astuto M, Bontempo P, Pignalosa O, Vietri MT, Molinari AM, Sica V, Della Corte F, Napoli C. The beneficial effects of antioxidant supplementation in enteral feeding in critically ill patients: A prospective, randomized, double- blind, placebo-controlled trial. Anesth Analg. 2004;99:857-863.
  • Michael ÉA, Arian M, Snežana S, Ivan S. Bench-to-bedside review: Sepsis - from the redox point of view. Crit Care. 2011;15:230.
  • Víctor VM, Espulgues JV, Hernández-Mijares A, Rocha M. Oxidative stress and mitochondrial dysfunction in sepsis: a potential therapy with mitochondria-targeted antioxidants. Infect Disord Drug Targets. 2009;9(4):376-389.
  • Ritter C, Andrades ME, Frota Junior ML, Bonatto F, Pinho RA, Polydoro M, Klamt F, Pinheiro CT, Menna-Barreto SS, Moreira JC, Dal-Pizzol F. Oxidative parameters and mortality in sepsis induced by cecal ligation and perforation. Intensive Care Med. 2003;29:1782-1789.
  • Iskit AB, Guc MO. Effects of endothelin and nitric oxide on organ injury, mesenteric ischemia and survival in experimental models of septic shock. Acta Pharmacol Sin. 2003;24:953-957.
  • Henriques GMOM. New therapeutic targets for the control of ınflammatory arthritis: a pivotal role for endothelins. 2013. ISBN 978- 953-51-0916-7. doi: 10.5772/53738.
  • Ehrenreich H, Burd PR, Rottem M Hültner L, Hylton JB, Garfield M, Coligan JE, Metcalfe DD, Fauci AS. Endothelins belong to the assortment of mast cell-derived and mast cell-bound cytokines. New Biol. 1992;4:147-156.
  • Endo T, Uchida Y, Matsumoto H Suzuki N, Nomura A, Hirata F, Hasegawa S. Regulation of endothelin-1 synthesis in cultured guinea pig airway epithelial cells by various cytokines. Biochem Biophys Res Commun. 1992;186:1594-1599.
  • Giaid A, Gibson SJ, Ibrahim BN, Legon S, Bloom SR, Yanagisawa M, Masaki T, Varndell IM, Polak JM. Endothelin 1, an endothelium- derived peptide, is expressed in neurons of the human spinal cord and dorsal root ganglia. Proc Natl Acad Sci. 1989;86:7634-7638.
  • Ehrenreich H. Endothelins, peptides with potent vasoactive properties are produced by human macrophages. J Exp Med. 1990;172:1741- 1748.
  • Takahashi K, Jones PM, Kanse SM, Lam HC, Spokes RA, Ghatei MA, Bloom SR. Endothelin in the gastrointestinal tract. Presence of endothelin-like immunoreactivity, endothelin-1 messenger RNA, endothelin receptors, and pharmacological effect. Gastroenterol. 1990;99:1660-1667.
  • Suzuki T, Kumazaki T, Mitsui Y. Endothelin-1 is produced and secreted by neonatal rat cardiac myocytes in vitro. Biochem Biophys Res Commun. 1993;191:823-830.
  • Rang HP, Dale MM, Ritter JM, Flower RJ, Henderson G. Control of vascular smooth muscle tone. Rang&Dale’s Pharmacology. 7th Ed USA: Elsevier, 2012. p. 268-271.
  • Masaki T. Endothelins: homeostatic and compensatory actions in the circulatory and endocrine systems. Endocr Rev. 1993;14(3):256-268.
  • Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature. 1990;348:730-732.
  • Barton M, Yanagisawa M. Endothelin: 20 years from discovery to therapy. Can J Physiol Pharmacol. 2008;86:485-498.
  • Pierce KL, Premont RT, Lefkowitz RJ. Seven-transmembrane receptors. Nat Rev Mol Cell Biol. 2002;3:639-650.
  • Sakurai T, Yanagisawa M, Takuwa Y, Miyazaki H, Kimura S, Goto K, Masaki T. Cloning of a cDNA encoding a non-isopeptideselective subtype of the endothelin receptor. Nature. 1990;348:732-735.
  • Bouallegue A, Daou GB, Srivastava AK. Endothelin-1-induced signaling pathways in vascular smooth muscle cells. Curr Vasc Pharmacol. 2007;5(1):45-52.
  • Duan J, Xu H, Dai S, Wang X, Wu Y, Zhang Y, Sun R, Ren J. Phytoestrogen alpha-zearalanol inhibits homocysteine-induced endothelin-1 expression and oxidative stress in human umbilical vein endothelial cells. Atherosclerosis. 2008;197:549-555.
  • Hukovic N, Hadziselimovic R. Endothelin 1 action on isolated rat stomach and the role of calcium ions in ET 1 induced depolarization of smooth muscle cells BC3H1. Biochem MolBiol Int. 1998;46:877-886.
  • Maemura K, Kurihara H, Morita T, Oh-hashi Y, Yazaki Y. Production of endothelin-1 in vascular endothelial cells is regulated by factors associated with vascular injury. Gerontology. 1992;38:29-35.
  • Sugiura M, Inagami T, Kon V. Endotoxin stimulates endothelin- release in vivo and in vitro as determined by radioimmunoassay. Biochem Biophys Res Commun. 1989;161:1220-1227.
  • Yanagisawa M, Kurihara H, Kimura S Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411-415.
  • Yamashita J, Ogawa M, Nomura K , Matsuo S, Inada K, Yamashita S, Nakashima Y, Saishoji T, Takano S, Fujita S. Interleukin 6 stimulates the production of immunoreactive endothelin 1 in human breast cancer cells. Cancer Res. 1993;53:464-546.
  • Yoshizumi M, Kurihara H, Sugiyama T, Takaku F, Yanagisawa M, Masaki T, Yazaki Y. Hemodynamic shear stress stimulates endothelin production by cultured endothelial cells. Biochem Biophys Res Commun. 1989;161:859-864.
  • Motte S, McEntee K, Naeije R. Endothelin receptor antagonists. Pharmacol Ther. 2006;110:386-414.
  • Hynynen MM, Khalil RA. The vascular endothelin system in hypertension-recent patents and discoveries. Recent Pat Cardiovasc Drug Discov. 2006;1:95-108.
  • Kowalczyk A, Kleniewska P, Kolodziejczyk M, Skibska B, Goraca A. The role of endothelin-1 and endothelin receptor antagonist in inflammatory response and sepsis. Arch Immunol Ther Exp. 2013; doi 10.1007/s00005-014-0310-1.
  • Lima VV, Giachini FR, Hardy DM ,Webb RC, Tostes RC. O-GlcNAcylation: a novel pathway contributing to the effects of endothelin in the vasculature. Am J Physiol Regul Integr Comp Physiol. 2011;300:236- 250.
  • Khalil RA. Modulators of the vascular endothelin receptor in blood pressure regulation and hypertension. Curr Mol Pharmacol. 2011;4:176-186.
  • Ohkita M, Tawa M, Kitada K Matsumura Y. Pathophysiological roles of endothelin receptors in cardiovascular diseases. J Pharmacol Sci. 2012;119:302-313.
  • Liu B, Zhou J, Chen H Wang D, Hu D, Wen Y, Xiao N. Expression and cellular location of endothelin-1 mRNA in rat liver following endotoxemia. Chin Med J. 1997;110:932-935.
  • Rodriguez MR, Soria LR, Ventimiglia MS, Najenson AC, Di María A, Dabas P, Fellet A, Marinelli RA, Vatta MS, Bianciotti LG. Endothelin-1 and -3 induce choleresis in the rat through ETB receptors coupled to nitric oxide and vagovagal reflexes. Clin Sci. 2013;125:521-532.
  • Abassi Z, Khateeb E, Ramadan R. The endothelin and pulmonary hypertension. Israeli Bilungual J Hypertens. 2010;16.
  • Beghetti M, Black SM, Fineman JR. Endothelin-1 in congenital heart disease. Pediatr Res. 2005;57:16-20.
  • Barton M, Yanagisawa M. Endothelin: 20 years from discovery to therapy. Can J Physiol Pharmacol. 2008;86:485-498.
  • Richard V. Endothelin: From discovery to pharmacotherapeutic innovations. Presse Med. 2014;43(7-8):742-755.
  • Weitzberg E, Lundberg JM, Rudehill A. Elevated plasma levels of endothelin in patients with sepsis syndrome. Circ Shock. 1991;33:222- 227.
  • Iskit AB, Guc MO. Effects of endothelin and nitric oxide on organ injury, mesenteric ischemia and survival in experimental models of septic shock. Acta Pharmacol Sin. 2003;24:953-957.
  • Iskit AB, Sungur A, Gedikoglu G, Guc MO. The effects of bosentan, aminoguanidine and L-canavanine on mesenteric blood flow, spleen and liver in endotoxaemic mice. Eur J Pharmacol. 1999;379:73-80.
  • Kavuklu B, Iskit AB, Guc MO, Ilhan M, Sayek I. Aminoguanidine attenuates endotoxin-induced mesenteric vascular hyporeactivity. Br J Surg. 2000;87:448-453.
  • Baykal A, Iskit AB, Hamaloglu E, Guc MO, Hascelik G, Sayek I. Melatonin modulates mesenteric blood flow and TNF alfa concentrations after lipopolysaccharide challenge. Eur J Surg. 2000;166:722-727.
  • Battistini B, M Forget DL. Potential roles for endothelins in systemic inflammatory response syndroik me with a particular relationship to cytokines. Shock. 1996;5:167-183.
  • Myhre U, HT Petterson C Risoe KE. Giercksky: Endothelin-1 and endotoxemia. J Cardiovasc Pharmacol. 1993;22:291-294.
  • Lin-Wang, C., C. Ying-Zi, T. Li-Jia, T. Jian, S. Jing-Yi T. Chao-Shu. Role of regulatory peptide in the pathogenesis of shock. Science in China. 1994;37:162-168.
  • Andrades ME, Ritter C, Dal-Pizzol F: The role of free radicals in sepsis development. Front Biosci. 2009;1:277-287.
  • Berger MM, Chioléro RL. Antioxidant supplementation in sepsis and systemic inflammatory response syndrome. Crit Care Med. 2007;35:584-590.
  • Crimi E, Liguori A, Condorelli M, Cioffi M, Astuto M, Bontempo P, Pignalosa O,Vietri MT, Molinari AM, Sica V, Della Corte F, Napoli C. The benefi cial eff ects of antioxidant supplementation in enteral feeding in critically ill patients: A prospective, randomized, double-blind, placebo-controlled trial. Anesth Analg. 2004;99:857-863.
  • Dong F, Zhang X, Wold LE Ren Q, Zhang Z, Ren J. Endothelin-1 enhances oxidative stress, cell proliferation and reduces apoptosis in human umbilical vein endothelial cells: role of ETB receptor, NADPH oxidase and caveolin-1. Br J Pharmacol. 2005;145:323-333.
  • Loomis ED, Sullivan JC, Osmond DA Pollock DM, Pollock JS. Endothelin mediates superoxide production and vasoconstriction through activation of NADPH oxidase and uncoupled nitric-oxide synthase in the rat aorta. J Pharmacol Exp Ther. 2005;315:1058-1064.
  • Lo´pez-Sepu´lveda R, Go´mez-Guzma´n M, Zarzuelo MJ Romero M, Sánchez M, Quintela AM, Galindo P, O’Valle F, Tamargo J, Pérez- Vizcaíno F, Duarte J, Jiménez R. Red wine polyphenols prevent endothelial dysfunction induced by endothelin-1 in rat aorta: role of NADPH oxidase. Clin Sci. 2011;120:321-333.
  • Michael Wanecek, Eddie Weitzberg, Anders Rudehill, Anders Oldner. The endothelin system in septic and endotoxin shock. Eur J Pharmacol. 2000;407:1-15.
  • Peyton MD, Hinshaw LB, Greenfield LJ, Elkins RC. The effects of coronary vasodilation on cardiac performance during endotoxin shock. Surg Gynecol Obstet. 1976;143:533-538.
  • Dhainaut JF., Huygebaert MF, Monsallier JF, Lefevre G, Dall’Ava- Santucci J, Brunet F, Villermant, D, Carli A, Raichvarg D. Coronary hemodynamics and myocardial metabolism of lactate, free fatty acids, glucose and ketones in patients with septic shock. Circulation. 1987;75:533-541.
  • Cunnion RE, Parillo JE. Myocardial dysfunction in sepsis. Crit Care Clin. 1989;5(1):99-118.
  • Goldfarb R, Nightingale L, Kish P, Loegering D. Left ventricular function during lethal and sub lethal endotoxemia in swine. Am J Physiol. 1986;251:364-373.
  • Bonggwan S, Oemar BS, Siebenmann R, von Segesser L, Luscher T.F. Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels. Circulation. 1994;89:1203-1208.
  • Awane Igata Y, Ikeda S, Watanabe T. Inhibitory effects of TAK-044 on endothelin induced vasoconstriction in various canine arteries and porcine coronary arteries: a comparison with selective ETA and ETB receptor antagonists. Br J Pharmacol. 1997;120:516-522.
  • Hohlfed T, Klemm P, Thiemermann C, Warner TD, Schror K, Vane JR. The contribution of tumour necrosis factor-alpha and endothelin-1 to the increase of coronary resistance in hearts from rats treated with endotoxin. Br J Pharmacol. 1995;116:3309-3315.
  • Granton JT, Goddard CM, Allard MF, van Eeden S, Walley KR. Leukocytes and decreased left-ventricular contractility during endotoxemia in rabbits. Am J Respir Crit Care Med. 1997;155:1977- 1983.
  • Lopez Farre A, Riesco A, Espinosa G, Digiuni E, Cernadas MR, Alvarez V, Montón M, Rivas F, Gallego MJ, Egido J. Effect of endothelin-1 on neutrophil adhesion to endothelial cells and perfused heart. Circulation. 1993;88:1166-1171.
  • Goddard CM, Allard MF, Hogg JC, Herbertson MJ, Walley KR. Prolonged leukocyte transit time in coronary microcirculation of endotoxemic pigs. Am J Physiol. 1995;269:1389-1397.
  • Bigatello L, Zapol M. New approaches to acute lung injury. Br J Anaesth. 1996;7:99-109.
  • Cassin S, Kristova V, Davis T, Kadowitz P, Gause G. Tone-dependent responses to endothelin in the isolated perfused fetal sheep pulmonary circulation in situ. J Appl Physiol. 1991;70:1228-1234.
  • Goldie RG, Knott PG, Carr MJ, Hay DW, Henry PJ. The endothelins in the pulmonary system. Pulm Pharmacol. 1996;9:69-93.
  • Svartholm E, Bregqvist D, Hedner U, Ljungberg J, Haglund U. Thrombaxane A2-receptor blockade and prostacyklin in porcine Escherichia coli shock. Arch Surg. 1989;124:669-672.
  • Curzen NP, Mitchell JA., Jourdan KB, Griffiths MJ, Evans TW. Endothelin- 1-induced contraction of pulmonary arteries from endotoxemic rat is attenuated by the endothelin-A receptor antagonist, BQ123. Crit Care Med. 1996;24:2007-2013.
  • Helset E, Ytrehus K, Tveita T, Kjeve J, Jorgensen L. Et-1 causes accumulation of leukocytes in the pulmonary circulation. Circ Shock. 1994;44:201-209.
  • Ishizuka T, Takamizawa Matsumoto M, Suzuki K, Kurita A. Endothelin-1 enhances vascular cell adhesion molecule-1 expression in tumor necrosis factor alfa-stimulated vascular endothelial cells. Eur J Pharmacol. 1999;369:237-245.
  • McCarron RM, Weang L, Stanimirovic DB, Spatz M. Endothelin induction of adhesion molecule expression on human brain microvascular endothelial cells. Neurosci Lett. 1993;156:31-34.
  • Humer MF, Phang PT, Friesen BP, Allard MF, Goddard CM, Walley KR. Heterogeneity of gut capillary transit times and impaired gut oxygen extraction in endotoxemic pigs. J Appl Physiol. 1996;81:895-904.
  • Lazaratos S, Kashimura H, Nakahara A, Fukutomi H, Osuga T, Urushidani T, Miyauchi T, Goto K. Gastric ulcer induced by submucosal injection of ET-1: role of potent vasoconstriction and intraluminal acid. Am J Physiol. 1993;265:491-498.
  • Whittle BJ, Lopez-Belmonte J. Actions and interactions of
  • endothelins, prostacyclin and nitric oxide in the gastric mucosa. J Physiol Pharmacol. 1993;44:91-107.
  • Michida T, Kawano S, Masuda E, Kobayashi I, Nishimura Y, Tsujii M, Hayashi N, Takei Y, Tsuji S, Nagano K. Role of endothelin-1 in hemorrhagic shock-induced gastric mucosal injury in rats. Gastroenterol. 1994;106:988-993.
  • Matsumaru K, Kashimura H, Hassan M, Nakahara A, Hayashi T, Iwata R, Goto K, Muto H, Tanaka N, Fukutomi H. Bosentan, a novel synthetic mixed-type endothelin receptor antagonist, attenuates acute gastric mucosal lesions induced by indomethacin and HCl in the rat: role of endogenous endothelin-1. J. Gastroenterol. 1997;32:164-170.
  • Kitajima T, Tani K, Yamaguchi T, Kubota Y, Okuhira M, Mizuno T, Inoue K. Role of endogenous endothelin in gastric mucosal injury induced by hemorrhagic shock in rats. Digestion. 1995;56:111-116.
  • Wilson MA, Steeb GD, Garrison RN. Endothelins mediate intestinal hypoperfusion during bacteremia. J Surg Res. 1993;55(2):168-175.
  • Pittet J, Morel D, Hemsen A, Gunning K, Lacroix JS, Suter P, Lundberg J. Elevated plasma endothelin-1 concentrations are associated with the severity of illness in patients with sepsis. Ann Surg. 1991;213:261- 264.
  • Bauer M, Zhang JX, Bauer I, Clemens MG. Endothelin-1 as a regulator of hepatic microcirculation: sublobular distribution of effects and impact on hepatocellular secretory function. Shock. 1994;1:457-465.
  • Iwai M, Yamaucohi T, Shimazu T. Endothelin 1 aggravates acute liver injury in perfused livers of rats after treatment with D-galactosamine. Hepatology. 1998;28:503-509.
  • Schulz E, Ruschitzka F, Lueders S, Heydenbluth R, Schrader J, Muller GA. Effects of endothelin on hemodynamics, prostaglandins, blood coagulation and renal function. Kidney Int. 1995;47:795-801.
  • Mitaka C, Hirata Y, Yokoyama K, Nagura T, Tsunoda Y, Amaha K. Improvement of renal dysfunction in dogs with endotoxemia by a nonselective endothelin receptor antagonist. Crit Care Med. 1999;27:146-153.
  • Yeager ME, Belchenko DD, Nguyen CM Colvin KL, Ivy DD, Stenmark KR. Endothelin-1, the unfolded protein response, and persistent inflammation: role of pulmonary artery smooth muscle cells. Am J Respir Cell Mol Biol. 2012;46:14-22.
  • Paulus P, Jennewein C, Zacharowsky K. Biomarkers of endothelial dysfunction: can they help us deciphering systemic inflammaton and sepsis. Biomarkers. 2011;16:11-21.

Sepsis ve septik şok patojenezinde endotelin-1’in rolü ve tedavide yeni yaklaşımlar

Year 2015, Volume: 5 Issue: 3, 178 - 190, 01.10.2015

Abstract

Vücuda giren patojene karşı gelişen sistemik enflamatuvar yanıt olarak adlandırılan sepsis, septik şok, çoklu organ yetmezliği ve ölümle sonuçlanabilmektedir. Sistemik enflamatuvar yanıtı tetikleyebilen artmış proenflamatuvar sitokin düzeyleriyle birlikte kemokinler, koagülasyon ve kompleman sistemleri ile vazoaktif aminler de sepsis patojenezinde yer almaktadır. Endotelin (ET)-1, 1988 yılında vazoaktif amin olarak damar endotelinden izole edilmiş olup 21 zincirli amino asit zincirine sahip bir peptitdir. (ET)-1’in sepsis ve septik şok gelişimindeki rolü deneysel ve klinik çalışmalarda gösterilmiş olup, reseptör antagonistleri sepsis tedavisinde denenmiş ve yararlı sonuçlar sağlamıştır. ET-1’in mitojenle etkinleştirilen protein kinaz sinyal ileti yolunu uyararak etkinleştirdiği downstream sinyal molekülleri aracılığıyla reaktif oksijen türlerinin üretiminde artış, enflamasyon gelişimi, endotelyal işlevde bozulma, anormal damar gerimi ve damarlarda yeniden modellenme gibi olaylara yol açarak sepsis, septik şok ve çoklu organ yetmezliği gelişiminde önemli rolü olabileceği düşünülmektedir.

References

  • Carré JE, Singer M. Cellular energetic metabolism in sepsis: the need for a systems approach. Biochim Biophys Acta. 2008;1777:763-771.
  • Fernandes D, Assreuy J. Nitric oxide and vascular reactivity in sepsis. Shock. 2008;30:10-13.
  • Tsiotou AG, Sakorafas GH, Anagnostopoulos G, Bramis J. Septic shock; current pathogenetic concepts from a clinical perspective. Med Sci Monit. 2005;11:76-85.
  • Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine Chest. 1992;101(6):644-655.
  • Kayaalp O. Otakoidler. Akılcı Tedavi Yönünden Tıbbi Farmakoloji. 13. Baskı. İstanbul: Güneş Tıp Kitabevi; 2012. s. 130-135.
  • Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001;29:1303-1310.
  • Aygen B, Kayabaş Ü, Güven M, Doğanay M, Sümerkan B, Yıldız O. Erciyes Üniversitesi Tıp Fakültesi yoğun bakım üniteleri nozokomial infeksiyonları sürveyansı: Epidemioloji, risk faktörleri ve prognozu etkileyen faktörler. Yoğun Bakım Dergisi. 2001;1:122-30.
  • Tunctan B, Korkmaz B, Sari AN, Kacan M, Unsal D, Serin MS, Buharalioglu CK, Sahan-Firat S, Schunck WH, Falck JR, Malik KU. A novel treatment strategy for sepsis and septic shock based on the interactions between prostanoids, nitric oxide, and 20-hydroxyeicosatetraenoic acid. Antiinflamm Antiallergy Agents Med Chem. 2012;11(2):121-150.
  • Vincent JL, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H, Moreno R, Carlet J, Le Gall JR, Payen D. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med. 2006;34(2):344- 353.
  • Dipiro JT, Talbert LR, Yee GC, Matzke GR,Wells GB, Posey ML. Sepsis and septic shock. Pharmacotherapy. 7th Ed. USA: McGraw-Hill Companies; 2008. p.1943-55.
  • Ünsal D. Sıçanlarda Zimosan ile Oluşan Hipotansiyona Dalak Tirozin Kinazının Katkısının Araştırılması. Mersin Üniversitesi Sağlık Bilimleri Enstitüsü; 2013.
  • Annane D, Bellissant E, Cavaillon JM. Septic shock. Lancet. 2005;365:63-78.
  • Raetz CR, Whitfield C. Lipopolysaccharide endotoxins. Annu Rev Biochem. 2002;71:635-700.
  • Beutler B, Cerami A. Tumor necrosis, cachexia, shock, and inflammation: a common mediator. Annu Rev Biochem. 1988;57:505- 518.
  • Miller SI, Ernst RK, Bader MW. LPS, TLR4 and infectious disease diversity. Nat Rev Microbiol. 2005;3:36-46.
  • Bryant CE, Spring DR, Gangloff M, Gay NJ. The molecular basis of the host response to lipopolysaccharide. Nat Rev Microbiol. 2010;8:8-14.
  • Agnieszka P, Aneta HJ, Kinga B, Ktarzynka K. Co-operation of TLR4 and raft proteins in LPS-induced pro-inflammatory signaling. Cell Mol Life Sci. 2015;72(3):557-581.
  • Reindert N, Tom H, Jos AG. Recognition of LPS by TLR4: Potential for anti-inflammatory therapies. Drugs. 2014;12(7):4260-4273.
  • Ramachandran G. Gram-positive and gram-negative bacterial toxins in sepsis: a brief review. Virulence. 2014;5(1):213-218.
  • Carvalho AC, Freeman NJ. How coagulation defects alter outcome in sepsis. J Crit Illn. 1994;9:51-75.
  • Kidokoro A, Iba T, Fukunaga M, Yagi Y. Alterations in coagulation and fibrinolysis during sepsis. Shock. 1996;5:223-228.
  • Vervloet MG, Thijs LG, Hack CE. Derangements of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock. Semin Thromb Hemost. 1998;24:33-44.
  • Aziz M1, Jacob A, Yang WL, Matsuda A, Wang P. Current trends in inflammatory and immunomodulatory mediators in sepsis. J Leukoc Biol. 2013;93(3):329-342.
  • Bone RC. The pathogenesis of sepsis. Ann Intern Med. 1991;115:457- 469.
  • Zhang Y, Zhao C, He W, Wang Z, Fang Q, Xiao B, Liu Z, Liang G, Yang S. Discovery and evaluation of asymmetrical monocarbonyl analogs of curcumin as antiinflammatory agents. Drug Des Devel Ther. 2014;8:373-382.
  • Sagy M, Al-Qaqaa Y, Kim P. Definitions and pathophysiology of sepsis. Curr Probl Pediatr Adolesc Health Care. 2013;43:260-263.
  • Roth J, De Souza GE. Fever induction pathways: evidence from responses to systemic or local cytokine formation. Braz J Med Biol Res. 2001;34:301-314.
  • Jesmin S, Shimojo N, Yamaguchi N Mowa CN, Oki M, Zaedi S, Sultana SN, Rahman A, Islam M, Sawamura A, Gando S, Kawano S, Miyauchi T, Mizutani T. Effects of protease activated receptor (PAR)2 blocking peptide on endothelin-1 levels in kidney tissues in endotoxemic rat mode. Life Sci. 2014;102:127-133.
  • Keller S, Karaa A, Paxian M Clemens MG, Zhang JX. Inhibition of endothelin- 1-mediated up-regulation of iNOS by bosentan ameliorates endotoxin-induced liver injury in cirrhosis. Shock. 2006;25:306-313.
  • Halliwell B, Gutteridge JMC: Free Radicals in Biology and Medicine. Oxford: Oxford University Press; 2007.
  • Andrades ME, Ritter C, Dal-Pizzol F: The role of free radicals in sepsis development. Front Biosci. 2009;1:277-287.
  • Berger MM, Chioléro RL. Antioxidant supplementation in sepsis and systemic inflammatory response syndrome. Crit Care Med. 2007;35:584-590.
  • Crimi E, Liguori A, Condorelli M, Cioffi M, Astuto M, Bontempo P, Pignalosa O, Vietri MT, Molinari AM, Sica V, Della Corte F, Napoli C. The beneficial effects of antioxidant supplementation in enteral feeding in critically ill patients: A prospective, randomized, double- blind, placebo-controlled trial. Anesth Analg. 2004;99:857-863.
  • Michael ÉA, Arian M, Snežana S, Ivan S. Bench-to-bedside review: Sepsis - from the redox point of view. Crit Care. 2011;15:230.
  • Víctor VM, Espulgues JV, Hernández-Mijares A, Rocha M. Oxidative stress and mitochondrial dysfunction in sepsis: a potential therapy with mitochondria-targeted antioxidants. Infect Disord Drug Targets. 2009;9(4):376-389.
  • Ritter C, Andrades ME, Frota Junior ML, Bonatto F, Pinho RA, Polydoro M, Klamt F, Pinheiro CT, Menna-Barreto SS, Moreira JC, Dal-Pizzol F. Oxidative parameters and mortality in sepsis induced by cecal ligation and perforation. Intensive Care Med. 2003;29:1782-1789.
  • Iskit AB, Guc MO. Effects of endothelin and nitric oxide on organ injury, mesenteric ischemia and survival in experimental models of septic shock. Acta Pharmacol Sin. 2003;24:953-957.
  • Henriques GMOM. New therapeutic targets for the control of ınflammatory arthritis: a pivotal role for endothelins. 2013. ISBN 978- 953-51-0916-7. doi: 10.5772/53738.
  • Ehrenreich H, Burd PR, Rottem M Hültner L, Hylton JB, Garfield M, Coligan JE, Metcalfe DD, Fauci AS. Endothelins belong to the assortment of mast cell-derived and mast cell-bound cytokines. New Biol. 1992;4:147-156.
  • Endo T, Uchida Y, Matsumoto H Suzuki N, Nomura A, Hirata F, Hasegawa S. Regulation of endothelin-1 synthesis in cultured guinea pig airway epithelial cells by various cytokines. Biochem Biophys Res Commun. 1992;186:1594-1599.
  • Giaid A, Gibson SJ, Ibrahim BN, Legon S, Bloom SR, Yanagisawa M, Masaki T, Varndell IM, Polak JM. Endothelin 1, an endothelium- derived peptide, is expressed in neurons of the human spinal cord and dorsal root ganglia. Proc Natl Acad Sci. 1989;86:7634-7638.
  • Ehrenreich H. Endothelins, peptides with potent vasoactive properties are produced by human macrophages. J Exp Med. 1990;172:1741- 1748.
  • Takahashi K, Jones PM, Kanse SM, Lam HC, Spokes RA, Ghatei MA, Bloom SR. Endothelin in the gastrointestinal tract. Presence of endothelin-like immunoreactivity, endothelin-1 messenger RNA, endothelin receptors, and pharmacological effect. Gastroenterol. 1990;99:1660-1667.
  • Suzuki T, Kumazaki T, Mitsui Y. Endothelin-1 is produced and secreted by neonatal rat cardiac myocytes in vitro. Biochem Biophys Res Commun. 1993;191:823-830.
  • Rang HP, Dale MM, Ritter JM, Flower RJ, Henderson G. Control of vascular smooth muscle tone. Rang&Dale’s Pharmacology. 7th Ed USA: Elsevier, 2012. p. 268-271.
  • Masaki T. Endothelins: homeostatic and compensatory actions in the circulatory and endocrine systems. Endocr Rev. 1993;14(3):256-268.
  • Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature. 1990;348:730-732.
  • Barton M, Yanagisawa M. Endothelin: 20 years from discovery to therapy. Can J Physiol Pharmacol. 2008;86:485-498.
  • Pierce KL, Premont RT, Lefkowitz RJ. Seven-transmembrane receptors. Nat Rev Mol Cell Biol. 2002;3:639-650.
  • Sakurai T, Yanagisawa M, Takuwa Y, Miyazaki H, Kimura S, Goto K, Masaki T. Cloning of a cDNA encoding a non-isopeptideselective subtype of the endothelin receptor. Nature. 1990;348:732-735.
  • Bouallegue A, Daou GB, Srivastava AK. Endothelin-1-induced signaling pathways in vascular smooth muscle cells. Curr Vasc Pharmacol. 2007;5(1):45-52.
  • Duan J, Xu H, Dai S, Wang X, Wu Y, Zhang Y, Sun R, Ren J. Phytoestrogen alpha-zearalanol inhibits homocysteine-induced endothelin-1 expression and oxidative stress in human umbilical vein endothelial cells. Atherosclerosis. 2008;197:549-555.
  • Hukovic N, Hadziselimovic R. Endothelin 1 action on isolated rat stomach and the role of calcium ions in ET 1 induced depolarization of smooth muscle cells BC3H1. Biochem MolBiol Int. 1998;46:877-886.
  • Maemura K, Kurihara H, Morita T, Oh-hashi Y, Yazaki Y. Production of endothelin-1 in vascular endothelial cells is regulated by factors associated with vascular injury. Gerontology. 1992;38:29-35.
  • Sugiura M, Inagami T, Kon V. Endotoxin stimulates endothelin- release in vivo and in vitro as determined by radioimmunoassay. Biochem Biophys Res Commun. 1989;161:1220-1227.
  • Yanagisawa M, Kurihara H, Kimura S Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411-415.
  • Yamashita J, Ogawa M, Nomura K , Matsuo S, Inada K, Yamashita S, Nakashima Y, Saishoji T, Takano S, Fujita S. Interleukin 6 stimulates the production of immunoreactive endothelin 1 in human breast cancer cells. Cancer Res. 1993;53:464-546.
  • Yoshizumi M, Kurihara H, Sugiyama T, Takaku F, Yanagisawa M, Masaki T, Yazaki Y. Hemodynamic shear stress stimulates endothelin production by cultured endothelial cells. Biochem Biophys Res Commun. 1989;161:859-864.
  • Motte S, McEntee K, Naeije R. Endothelin receptor antagonists. Pharmacol Ther. 2006;110:386-414.
  • Hynynen MM, Khalil RA. The vascular endothelin system in hypertension-recent patents and discoveries. Recent Pat Cardiovasc Drug Discov. 2006;1:95-108.
  • Kowalczyk A, Kleniewska P, Kolodziejczyk M, Skibska B, Goraca A. The role of endothelin-1 and endothelin receptor antagonist in inflammatory response and sepsis. Arch Immunol Ther Exp. 2013; doi 10.1007/s00005-014-0310-1.
  • Lima VV, Giachini FR, Hardy DM ,Webb RC, Tostes RC. O-GlcNAcylation: a novel pathway contributing to the effects of endothelin in the vasculature. Am J Physiol Regul Integr Comp Physiol. 2011;300:236- 250.
  • Khalil RA. Modulators of the vascular endothelin receptor in blood pressure regulation and hypertension. Curr Mol Pharmacol. 2011;4:176-186.
  • Ohkita M, Tawa M, Kitada K Matsumura Y. Pathophysiological roles of endothelin receptors in cardiovascular diseases. J Pharmacol Sci. 2012;119:302-313.
  • Liu B, Zhou J, Chen H Wang D, Hu D, Wen Y, Xiao N. Expression and cellular location of endothelin-1 mRNA in rat liver following endotoxemia. Chin Med J. 1997;110:932-935.
  • Rodriguez MR, Soria LR, Ventimiglia MS, Najenson AC, Di María A, Dabas P, Fellet A, Marinelli RA, Vatta MS, Bianciotti LG. Endothelin-1 and -3 induce choleresis in the rat through ETB receptors coupled to nitric oxide and vagovagal reflexes. Clin Sci. 2013;125:521-532.
  • Abassi Z, Khateeb E, Ramadan R. The endothelin and pulmonary hypertension. Israeli Bilungual J Hypertens. 2010;16.
  • Beghetti M, Black SM, Fineman JR. Endothelin-1 in congenital heart disease. Pediatr Res. 2005;57:16-20.
  • Barton M, Yanagisawa M. Endothelin: 20 years from discovery to therapy. Can J Physiol Pharmacol. 2008;86:485-498.
  • Richard V. Endothelin: From discovery to pharmacotherapeutic innovations. Presse Med. 2014;43(7-8):742-755.
  • Weitzberg E, Lundberg JM, Rudehill A. Elevated plasma levels of endothelin in patients with sepsis syndrome. Circ Shock. 1991;33:222- 227.
  • Iskit AB, Guc MO. Effects of endothelin and nitric oxide on organ injury, mesenteric ischemia and survival in experimental models of septic shock. Acta Pharmacol Sin. 2003;24:953-957.
  • Iskit AB, Sungur A, Gedikoglu G, Guc MO. The effects of bosentan, aminoguanidine and L-canavanine on mesenteric blood flow, spleen and liver in endotoxaemic mice. Eur J Pharmacol. 1999;379:73-80.
  • Kavuklu B, Iskit AB, Guc MO, Ilhan M, Sayek I. Aminoguanidine attenuates endotoxin-induced mesenteric vascular hyporeactivity. Br J Surg. 2000;87:448-453.
  • Baykal A, Iskit AB, Hamaloglu E, Guc MO, Hascelik G, Sayek I. Melatonin modulates mesenteric blood flow and TNF alfa concentrations after lipopolysaccharide challenge. Eur J Surg. 2000;166:722-727.
  • Battistini B, M Forget DL. Potential roles for endothelins in systemic inflammatory response syndroik me with a particular relationship to cytokines. Shock. 1996;5:167-183.
  • Myhre U, HT Petterson C Risoe KE. Giercksky: Endothelin-1 and endotoxemia. J Cardiovasc Pharmacol. 1993;22:291-294.
  • Lin-Wang, C., C. Ying-Zi, T. Li-Jia, T. Jian, S. Jing-Yi T. Chao-Shu. Role of regulatory peptide in the pathogenesis of shock. Science in China. 1994;37:162-168.
  • Andrades ME, Ritter C, Dal-Pizzol F: The role of free radicals in sepsis development. Front Biosci. 2009;1:277-287.
  • Berger MM, Chioléro RL. Antioxidant supplementation in sepsis and systemic inflammatory response syndrome. Crit Care Med. 2007;35:584-590.
  • Crimi E, Liguori A, Condorelli M, Cioffi M, Astuto M, Bontempo P, Pignalosa O,Vietri MT, Molinari AM, Sica V, Della Corte F, Napoli C. The benefi cial eff ects of antioxidant supplementation in enteral feeding in critically ill patients: A prospective, randomized, double-blind, placebo-controlled trial. Anesth Analg. 2004;99:857-863.
  • Dong F, Zhang X, Wold LE Ren Q, Zhang Z, Ren J. Endothelin-1 enhances oxidative stress, cell proliferation and reduces apoptosis in human umbilical vein endothelial cells: role of ETB receptor, NADPH oxidase and caveolin-1. Br J Pharmacol. 2005;145:323-333.
  • Loomis ED, Sullivan JC, Osmond DA Pollock DM, Pollock JS. Endothelin mediates superoxide production and vasoconstriction through activation of NADPH oxidase and uncoupled nitric-oxide synthase in the rat aorta. J Pharmacol Exp Ther. 2005;315:1058-1064.
  • Lo´pez-Sepu´lveda R, Go´mez-Guzma´n M, Zarzuelo MJ Romero M, Sánchez M, Quintela AM, Galindo P, O’Valle F, Tamargo J, Pérez- Vizcaíno F, Duarte J, Jiménez R. Red wine polyphenols prevent endothelial dysfunction induced by endothelin-1 in rat aorta: role of NADPH oxidase. Clin Sci. 2011;120:321-333.
  • Michael Wanecek, Eddie Weitzberg, Anders Rudehill, Anders Oldner. The endothelin system in septic and endotoxin shock. Eur J Pharmacol. 2000;407:1-15.
  • Peyton MD, Hinshaw LB, Greenfield LJ, Elkins RC. The effects of coronary vasodilation on cardiac performance during endotoxin shock. Surg Gynecol Obstet. 1976;143:533-538.
  • Dhainaut JF., Huygebaert MF, Monsallier JF, Lefevre G, Dall’Ava- Santucci J, Brunet F, Villermant, D, Carli A, Raichvarg D. Coronary hemodynamics and myocardial metabolism of lactate, free fatty acids, glucose and ketones in patients with septic shock. Circulation. 1987;75:533-541.
  • Cunnion RE, Parillo JE. Myocardial dysfunction in sepsis. Crit Care Clin. 1989;5(1):99-118.
  • Goldfarb R, Nightingale L, Kish P, Loegering D. Left ventricular function during lethal and sub lethal endotoxemia in swine. Am J Physiol. 1986;251:364-373.
  • Bonggwan S, Oemar BS, Siebenmann R, von Segesser L, Luscher T.F. Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels. Circulation. 1994;89:1203-1208.
  • Awane Igata Y, Ikeda S, Watanabe T. Inhibitory effects of TAK-044 on endothelin induced vasoconstriction in various canine arteries and porcine coronary arteries: a comparison with selective ETA and ETB receptor antagonists. Br J Pharmacol. 1997;120:516-522.
  • Hohlfed T, Klemm P, Thiemermann C, Warner TD, Schror K, Vane JR. The contribution of tumour necrosis factor-alpha and endothelin-1 to the increase of coronary resistance in hearts from rats treated with endotoxin. Br J Pharmacol. 1995;116:3309-3315.
  • Granton JT, Goddard CM, Allard MF, van Eeden S, Walley KR. Leukocytes and decreased left-ventricular contractility during endotoxemia in rabbits. Am J Respir Crit Care Med. 1997;155:1977- 1983.
  • Lopez Farre A, Riesco A, Espinosa G, Digiuni E, Cernadas MR, Alvarez V, Montón M, Rivas F, Gallego MJ, Egido J. Effect of endothelin-1 on neutrophil adhesion to endothelial cells and perfused heart. Circulation. 1993;88:1166-1171.
  • Goddard CM, Allard MF, Hogg JC, Herbertson MJ, Walley KR. Prolonged leukocyte transit time in coronary microcirculation of endotoxemic pigs. Am J Physiol. 1995;269:1389-1397.
  • Bigatello L, Zapol M. New approaches to acute lung injury. Br J Anaesth. 1996;7:99-109.
  • Cassin S, Kristova V, Davis T, Kadowitz P, Gause G. Tone-dependent responses to endothelin in the isolated perfused fetal sheep pulmonary circulation in situ. J Appl Physiol. 1991;70:1228-1234.
  • Goldie RG, Knott PG, Carr MJ, Hay DW, Henry PJ. The endothelins in the pulmonary system. Pulm Pharmacol. 1996;9:69-93.
  • Svartholm E, Bregqvist D, Hedner U, Ljungberg J, Haglund U. Thrombaxane A2-receptor blockade and prostacyklin in porcine Escherichia coli shock. Arch Surg. 1989;124:669-672.
  • Curzen NP, Mitchell JA., Jourdan KB, Griffiths MJ, Evans TW. Endothelin- 1-induced contraction of pulmonary arteries from endotoxemic rat is attenuated by the endothelin-A receptor antagonist, BQ123. Crit Care Med. 1996;24:2007-2013.
  • Helset E, Ytrehus K, Tveita T, Kjeve J, Jorgensen L. Et-1 causes accumulation of leukocytes in the pulmonary circulation. Circ Shock. 1994;44:201-209.
  • Ishizuka T, Takamizawa Matsumoto M, Suzuki K, Kurita A. Endothelin-1 enhances vascular cell adhesion molecule-1 expression in tumor necrosis factor alfa-stimulated vascular endothelial cells. Eur J Pharmacol. 1999;369:237-245.
  • McCarron RM, Weang L, Stanimirovic DB, Spatz M. Endothelin induction of adhesion molecule expression on human brain microvascular endothelial cells. Neurosci Lett. 1993;156:31-34.
  • Humer MF, Phang PT, Friesen BP, Allard MF, Goddard CM, Walley KR. Heterogeneity of gut capillary transit times and impaired gut oxygen extraction in endotoxemic pigs. J Appl Physiol. 1996;81:895-904.
  • Lazaratos S, Kashimura H, Nakahara A, Fukutomi H, Osuga T, Urushidani T, Miyauchi T, Goto K. Gastric ulcer induced by submucosal injection of ET-1: role of potent vasoconstriction and intraluminal acid. Am J Physiol. 1993;265:491-498.
  • Whittle BJ, Lopez-Belmonte J. Actions and interactions of
  • endothelins, prostacyclin and nitric oxide in the gastric mucosa. J Physiol Pharmacol. 1993;44:91-107.
  • Michida T, Kawano S, Masuda E, Kobayashi I, Nishimura Y, Tsujii M, Hayashi N, Takei Y, Tsuji S, Nagano K. Role of endothelin-1 in hemorrhagic shock-induced gastric mucosal injury in rats. Gastroenterol. 1994;106:988-993.
  • Matsumaru K, Kashimura H, Hassan M, Nakahara A, Hayashi T, Iwata R, Goto K, Muto H, Tanaka N, Fukutomi H. Bosentan, a novel synthetic mixed-type endothelin receptor antagonist, attenuates acute gastric mucosal lesions induced by indomethacin and HCl in the rat: role of endogenous endothelin-1. J. Gastroenterol. 1997;32:164-170.
  • Kitajima T, Tani K, Yamaguchi T, Kubota Y, Okuhira M, Mizuno T, Inoue K. Role of endogenous endothelin in gastric mucosal injury induced by hemorrhagic shock in rats. Digestion. 1995;56:111-116.
  • Wilson MA, Steeb GD, Garrison RN. Endothelins mediate intestinal hypoperfusion during bacteremia. J Surg Res. 1993;55(2):168-175.
  • Pittet J, Morel D, Hemsen A, Gunning K, Lacroix JS, Suter P, Lundberg J. Elevated plasma endothelin-1 concentrations are associated with the severity of illness in patients with sepsis. Ann Surg. 1991;213:261- 264.
  • Bauer M, Zhang JX, Bauer I, Clemens MG. Endothelin-1 as a regulator of hepatic microcirculation: sublobular distribution of effects and impact on hepatocellular secretory function. Shock. 1994;1:457-465.
  • Iwai M, Yamaucohi T, Shimazu T. Endothelin 1 aggravates acute liver injury in perfused livers of rats after treatment with D-galactosamine. Hepatology. 1998;28:503-509.
  • Schulz E, Ruschitzka F, Lueders S, Heydenbluth R, Schrader J, Muller GA. Effects of endothelin on hemodynamics, prostaglandins, blood coagulation and renal function. Kidney Int. 1995;47:795-801.
  • Mitaka C, Hirata Y, Yokoyama K, Nagura T, Tsunoda Y, Amaha K. Improvement of renal dysfunction in dogs with endotoxemia by a nonselective endothelin receptor antagonist. Crit Care Med. 1999;27:146-153.
  • Yeager ME, Belchenko DD, Nguyen CM Colvin KL, Ivy DD, Stenmark KR. Endothelin-1, the unfolded protein response, and persistent inflammation: role of pulmonary artery smooth muscle cells. Am J Respir Cell Mol Biol. 2012;46:14-22.
  • Paulus P, Jennewein C, Zacharowsky K. Biomarkers of endothelial dysfunction: can they help us deciphering systemic inflammaton and sepsis. Biomarkers. 2011;16:11-21.
There are 118 citations in total.

Details

Primary Language Turkish
Journal Section Articles
Authors

Demet Sinem Güden This is me

Meryem Temiz This is me

Bahar Tunçtan This is me

Seyhan Şahan Fırat

Publication Date October 1, 2015
Submission Date October 1, 2015
Published in Issue Year 2015 Volume: 5 Issue: 3

Cite

APA Güden, D. S., Temiz, M., Tunçtan, B., Şahan Fırat, S. (2015). Sepsis ve septik şok patojenezinde endotelin-1’in rolü ve tedavide yeni yaklaşımlar. Clinical and Experimental Health Sciences, 5(3), 178-190. https://doi.org/10.5455/musbed.20150602023809
AMA Güden DS, Temiz M, Tunçtan B, Şahan Fırat S. Sepsis ve septik şok patojenezinde endotelin-1’in rolü ve tedavide yeni yaklaşımlar. Clinical and Experimental Health Sciences. October 2015;5(3):178-190. doi:10.5455/musbed.20150602023809
Chicago Güden, Demet Sinem, Meryem Temiz, Bahar Tunçtan, and Seyhan Şahan Fırat. “Sepsis Ve Septik şok Patojenezinde Endotelin-1’in Rolü Ve Tedavide Yeni yaklaşımlar”. Clinical and Experimental Health Sciences 5, no. 3 (October 2015): 178-90. https://doi.org/10.5455/musbed.20150602023809.
EndNote Güden DS, Temiz M, Tunçtan B, Şahan Fırat S (October 1, 2015) Sepsis ve septik şok patojenezinde endotelin-1’in rolü ve tedavide yeni yaklaşımlar. Clinical and Experimental Health Sciences 5 3 178–190.
IEEE D. S. Güden, M. Temiz, B. Tunçtan, and S. Şahan Fırat, “Sepsis ve septik şok patojenezinde endotelin-1’in rolü ve tedavide yeni yaklaşımlar”, Clinical and Experimental Health Sciences, vol. 5, no. 3, pp. 178–190, 2015, doi: 10.5455/musbed.20150602023809.
ISNAD Güden, Demet Sinem et al. “Sepsis Ve Septik şok Patojenezinde Endotelin-1’in Rolü Ve Tedavide Yeni yaklaşımlar”. Clinical and Experimental Health Sciences 5/3 (October 2015), 178-190. https://doi.org/10.5455/musbed.20150602023809.
JAMA Güden DS, Temiz M, Tunçtan B, Şahan Fırat S. Sepsis ve septik şok patojenezinde endotelin-1’in rolü ve tedavide yeni yaklaşımlar. Clinical and Experimental Health Sciences. 2015;5:178–190.
MLA Güden, Demet Sinem et al. “Sepsis Ve Septik şok Patojenezinde Endotelin-1’in Rolü Ve Tedavide Yeni yaklaşımlar”. Clinical and Experimental Health Sciences, vol. 5, no. 3, 2015, pp. 178-90, doi:10.5455/musbed.20150602023809.
Vancouver Güden DS, Temiz M, Tunçtan B, Şahan Fırat S. Sepsis ve septik şok patojenezinde endotelin-1’in rolü ve tedavide yeni yaklaşımlar. Clinical and Experimental Health Sciences. 2015;5(3):178-90.

14639   14640